T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
about
Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant allelesAutoimmune dysregulation and purine metabolism in adenosine deaminase deficiency.Nasopharyngeal tonsils (adenoids) contain extrathymic corticothymocytes.polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiencyPlacental transfer of maternally-derived IgA precludes the use of guthrie card eluates as a screening tool for primary immunodeficiency diseases.Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.Clinical applications of gene therapy for primary immunodeficiencies.Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.Glutamate synthesis via photoreduction of NADP+ by photostable chlorophyllide coupled with polyethylene-glycol.First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.Hyaluronan conjugation of antigenic protein to modify immunogenic information
P2860
Q24539210-18B964CA-4EBB-4283-BAE0-808CED01D1D8Q33403252-788A15A8-A857-4AAF-8825-4927165DDB8FQ33655149-34E2DFBF-87D6-4984-811C-080124186A62Q33910797-C37A1452-2DE6-4404-8C60-62919E703A46Q34391579-82560DB7-47D6-4586-AFC4-30E9DEC49139Q35284944-EE8CBAE6-0AD3-45DB-9196-84962D1D2E36Q35539617-E1C9C271-3841-49CB-9525-BE5B2537CAE6Q36713570-352EA41C-AEC9-41D6-9B97-6457F7823B85Q37182935-F7144256-71EF-45F6-8A19-33ED2A65710DQ37586932-E341902B-8BBF-413F-9E47-0FF68C633806Q37664729-6B676850-62A0-4B3E-B9DF-1E2737C99890Q41872915-8BA5121F-BA6B-4A8D-B24A-E2D59D822CE7Q43635618-D4449C73-1217-4091-863D-9DFF8107FC6FQ49884908-F52D066E-E5D2-40CB-8494-595CCD440227Q57744087-596F145E-1842-44F9-B145-A37EF553106C
P2860
T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
description
1993 nî lūn-bûn
@nan
1993 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@ast
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@en
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@nl
type
label
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@ast
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@en
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@nl
prefLabel
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@ast
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@en
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@nl
P2093
P2860
P356
P1476
T lymphocyte ontogeny in adeno ...... -modified adenosine deaminase.
@en
P2093
C Lenarsky
K Weinberg
M S Hershfield
P2860
P304
P356
10.1172/JCI116626
P407
P577
1993-08-01T00:00:00Z